Clin2
NCT07559240Possibly a fitNot yet recruiting

How Your Kidneys Handle a New Diabetes Medicine

OverweightObese

Part of Hormones & metabolism clinical trials.

This study tests how a new injectable medicine called HDM1005 works in your body, with special attention to how your kidneys process it. Researchers want to understand if the medicine is safe for people with kidney problems and healthy people.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
30 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Be between 18 and 75 years old
  • Weigh at least 50 kg (110 lbs) if male or 45 kg (99 lbs) if female
  • Have a BMI (body mass index) between 19 and 35
  • If you have kidney disease, it must be chronic (long-term) and not due to blocked urine flow or recent kidney injury
  • No history of medullary thyroid cancer, thyroid growths, or MEN2 syndrome
  • No severe or frequent low blood sugar episodes in the past 3 months, no recent pancreas or gallbladder problems

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07502001Not yet recruiting· Phase 1
How HDM1005 affects common drugs

This study tests how a new medication (HDM1005) affects the way your body absorbs and processes common drugs like metformin, atorvastatin, warfarin, and digoxin. It is for healthy volunteers to understand potential interactions before further testing.

Hefei
NCT07394114Recruiting· Phase 3
Study of a new medicine for type 2 diabetes not controlled by diet and exercise

This trial tests a new medicine called HDM1005 for people with type 2 diabetes who haven't been helped enough by diet and exercise alone, and who haven't taken any diabetes medication in the last 12 weeks. It aims to see if the medicine can help lower blood sugar levels safely.

Beijing
NCT07417306Not yet recruiting· Phase 3
New drug for type 2 diabetes not well controlled on metformin

This trial tests an investigational drug called HDM1005 for people with type 2 diabetes whose blood sugar is still high despite taking metformin (with or without another diabetes pill called an SGLT2 inhibitor). The goal is to see if the new drug can better lower blood sugar levels.

Beijing
NCT07109700Recruiting· Phase 2
New injectable study for type 2 diabetes

This study tests a new once-weekly injectable medication (HDM1005) for people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise or metformin alone. It aims to help lower blood sugar and may also support weight loss.

Beijing, Beijing Municipality
NCT06601517Not yet recruiting· Phase 1
Study of drug interactions with HDM1002 in healthy and overweight adults

This trial tests how a new medicine, HDM1002, interacts with four common drugs (repaglinide, atorvastatin, digoxin, rosuvastatin) in healthy and overweight adults. The results will help guide safe dosing for future patients.

Beijing
NCT06666283Recruiting· Phase 1
Testing a new drug for diabetic kidney disease

This study tests a new medicine called AP303 for people with type 2 diabetes and chronic kidney disease. The goal is to see if it is safe and how the body processes it. If you have diabetes and your kidneys are not working as well as they used to, this trial might help find new treatment options.

Beijing, Beijing Municipality

Hear when a new Overweight trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.